<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S1359644620301720</prism:url><dc:identifier>doi:10.1016/j.drudis.2020.04.023</dc:identifier><eid>1-s2.0-S1359644620301720</eid><prism:doi>10.1016/j.drudis.2020.04.023</prism:doi><pii>S1359-6446(20)30172-0</pii><dc:title>Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside </dc:title><prism:publicationName>Drug Discovery Today</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>fla</pubtype><prism:issn>13596446</prism:issn><prism:volume>25</prism:volume><prism:issueIdentifier>7</prism:issueidentifier><prism:startingPage>1189</prism:startingpage><prism:endingPage>1197</prism:endingpage><prism:pageRange>1189-1197</prism:pagerange><prism:number>7</prism:number><dc:format>text/xml</dc:format><prism:coverDate>2020-07-31</prism:coverdate><prism:coverDisplayDate>July 2020</prism:coverdisplaydate><prism:copyright>© 2020 Elsevier Ltd. All rights reserved.</prism:copyright><prism:publisher>Elsevier Ltd.</prism:publisher><dc:creator>Houssein, Marwa</dc:creator><dc:creator>Khalil, Mahmoud</dc:creator><dc:creator>Fatfat, Maamoun</dc:creator><dc:creator>Gali-Muhtasib, Hala</dc:creator><dc:description>
                  Human T cell lymphotropic virus-1 (HTLV-1) is the causative agent of adult T cell leukemia (ATL), an aggressive malignancy of mature activated T cells. Although many therapeutic strategies are available, none are effective and most patients experience recurrence of the disease. Over the past decade, many drugs have been discovered that showed promising therapeutic potential against ATL but which remain in the preclinical testing phase. Mechanistically, these drugs either induce apoptosis or regulate cellular proliferation in ATL cells. Here, we provide a summary of these promising drugs that target ATL, with a focus on their mechanism of anticancer activity, to offer insights into the use of multiple drugs with different targets for enhancing ATL eradication.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><link href="https://api.elsevier.com/content/article/pii/S1359644620301720" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S1359644620301720" rel="scidir"/></link></coredata><objects><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="836" height="863" size="107875">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620301720-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="837" height="800" size="103666">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620301720-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="159" height="164" size="9535">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620301720-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="171" height="163" size="8681">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620301720-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3703" height="3822" size="995088">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620301720-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3704" height="3540" size="887097">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620301720-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="am" category="standard" type="AAM-PDF" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="765094">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644620301720-am.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>85084980337</scopus-id><scopus-eid>2-s2.0-85084980337</scopus-eid><pubmed-id>32389641</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85084980337" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271275</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291727</xocs:ssid>
         <xocs:ssid type="subj">291850</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>Drug Discovery Today</xocs:srctitle>
      <xocs:normalized-srctitle>DRUGDISCOVERYTODAY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20200507">2020-05-07</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20200507">2020-05-07</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20200723">2020-07-23</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20200723">2020-07-23</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2020-07-23T16:53:12</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S1359644620301720</xocs:eid>
      <xocs:pii-formatted>S1359-6446(20)30172-0</xocs:pii-formatted>
      <xocs:pii-unformatted>S1359644620301720</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.drudis.2020.04.023</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S1359644620X00080</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20210130">2021-01-30T05:30:23.899605Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20200701</xocs:date-search-begin>
      <xocs:date-search-end>20200731</xocs:date-search-end>
      <xocs:year-nav>2020</xocs:year-nav>
      <xocs:indexeddate epoch="1588865155">2020-05-07T15:25:55.41861Z</xocs:indexeddate>
      <xocs:articleinfo>articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issfirst issn issnnorm issuelist itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pglast pii piinorm pubdateend pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table body affil articletitle auth authfirstini authfull authlast highlightsabst orcid primabst pubtype ref</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>1359-6446</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>13596446</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>25</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>25</xocs:volume>
      </xocs:volume-list>
      <xocs:iss-first>7</xocs:iss-first>
      <xocs:issue-list>
         <xocs:issue>7</xocs:issue>
      </xocs:issue-list>
      <xocs:vol-iss-suppl-text>Volume 25, Issue 7</xocs:vol-iss-suppl-text>
      <xocs:sort-order>12</xocs:sort-order>
      <xocs:first-fp>1189</xocs:first-fp>
      <xocs:last-lp>1197</xocs:last-lp>
      <xocs:pages>
         <xocs:first-page>1189</xocs:first-page>
         <xocs:last-page>1197</xocs:last-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>202007</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>July 2020</xocs:cover-date-text>
      <xocs:cover-date-start>2020-07-01</xocs:cover-date-start>
      <xocs:cover-date-end>2020-07-31</xocs:cover-date-end>
      <xocs:cover-date-year>2020</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>REVIEWS</xocs:hub-sec-title>
         <xocs:hub-sec>
            <xocs:hub-sec-title>Gene to Screen</xocs:hub-sec-title>
         </xocs:hub-sec>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>© 2020 Elsevier Ltd. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>APOPTOSISAMECHANISMFORTREATMENTADULTTCELLLEUKEMIAPROMISINGDRUGSBENCHSIDEBEDSIDE</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>HOUSSEIN</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>M</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Apoptosis and cancer</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>HTLV: the causative agent of ATL</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Targeted chemotherapy for ATL: promising preclinical drugs</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Targeting nuclear factor kappa beta</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Targeting PI3K/AKT cascade</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Targeting JAK-STAT pathway</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Targeting apoptosis pathways</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Concluding remarks</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sbref0005">
            <xocs:ref-normalized-surname>WATANABE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1071</xocs:ref-first-fp>
            <xocs:ref-last-lp>1082</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0010">
            <xocs:ref-normalized-surname>CZABOTAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>49</xocs:ref-first-fp>
            <xocs:ref-last-lp>63</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0015">
            <xocs:ref-normalized-surname>WONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>30</xocs:ref-first-fp>
            <xocs:ref-last-lp>87</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0020">
            <xocs:ref-normalized-surname>SHIMOYAMA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1991</xocs:ref-pub-year>
            <xocs:ref-first-fp>428</xocs:ref-first-fp>
            <xocs:ref-last-lp>437</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0025">
            <xocs:ref-normalized-surname>BALDWIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1996</xocs:ref-pub-year>
            <xocs:ref-first-fp>649</xocs:ref-first-fp>
            <xocs:ref-last-lp>683</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0030">
            <xocs:ref-normalized-surname>PORTIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>1200</xocs:ref-first-fp>
            <xocs:ref-last-lp>1208</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0035">
            <xocs:ref-normalized-surname>CHIE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>633</xocs:ref-first-fp>
            <xocs:ref-last-lp>643</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0040">
            <xocs:ref-normalized-surname>CHIE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>633</xocs:ref-first-fp>
            <xocs:ref-last-lp>643</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0045">
            <xocs:ref-normalized-surname>ISHIKAWA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>2702</xocs:ref-first-fp>
            <xocs:ref-last-lp>2712</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0050">
            <xocs:ref-normalized-surname>TAEKO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>704</xocs:ref-first-fp>
            <xocs:ref-last-lp>712</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0055">
            <xocs:ref-normalized-surname>NAOKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>1828</xocs:ref-first-fp>
            <xocs:ref-last-lp>1834</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0060">
            <xocs:ref-normalized-surname>SHVARZBEYN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>108</xocs:ref-first-fp>
            <xocs:ref-last-lp>115</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0065">
            <xocs:ref-normalized-surname>MACHIJIMA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>7</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0070">
            <xocs:ref-normalized-surname>NAKAZATO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>2286</xocs:ref-first-fp>
            <xocs:ref-last-lp>2294</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0075">
            <xocs:ref-normalized-surname>YAMAGUCHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>1010</xocs:ref-first-fp>
            <xocs:ref-last-lp>1017</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0080">
            <xocs:ref-normalized-surname>MARIKO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>2462</xocs:ref-first-fp>
            <xocs:ref-last-lp>2471</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0085">
            <xocs:ref-normalized-surname>NISHIOKA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>1044</xocs:ref-first-fp>
            <xocs:ref-last-lp>1049</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0090">
            <xocs:ref-normalized-surname>NORI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>829</xocs:ref-first-fp>
            <xocs:ref-last-lp>842</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0095">
            <xocs:ref-normalized-surname>YAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>600</xocs:ref-first-fp>
            <xocs:ref-last-lp>603</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0100">
            <xocs:ref-normalized-surname>CHIE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>387</xocs:ref-first-fp>
            <xocs:ref-last-lp>392</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0105">
            <xocs:ref-normalized-surname>DEWAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>716</xocs:ref-first-fp>
            <xocs:ref-last-lp>724</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0110">
            <xocs:ref-normalized-surname>WEST</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>234</xocs:ref-first-fp>
            <xocs:ref-last-lp>248</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0115">
            <xocs:ref-normalized-surname>WATANABE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>497</xocs:ref-first-fp>
            <xocs:ref-last-lp>500</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0120">
            <xocs:ref-normalized-surname>GUTIERREZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>647</xocs:ref-first-fp>
            <xocs:ref-last-lp>650</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0125">
            <xocs:ref-normalized-surname>MASAAKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>6966</xocs:ref-first-fp>
            <xocs:ref-last-lp>6977</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0130">
            <xocs:ref-normalized-surname>HIROO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>24</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0135">
            <xocs:ref-normalized-surname>IKEZOE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>673</xocs:ref-first-fp>
            <xocs:ref-last-lp>682</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0140">
            <xocs:ref-normalized-surname>ISHIKAWA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>5311</xocs:ref-first-fp>
            <xocs:ref-last-lp>5317</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0145">
            <xocs:ref-normalized-surname>DARWICHE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>993</xocs:ref-first-fp>
            <xocs:ref-last-lp>1004</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0150">
            <xocs:ref-normalized-surname>WATANABE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>95</xocs:ref-first-fp>
            <xocs:ref-last-lp>102</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0155">
            <xocs:ref-normalized-surname>SINHADATTA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>33</xocs:ref-first-fp>
            <xocs:ref-last-lp>40</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>U</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0160">
            <xocs:ref-normalized-surname>OKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>463</xocs:ref-first-fp>
            <xocs:ref-last-lp>470</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0165">
            <xocs:ref-normalized-surname>IYER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0170">
            <xocs:ref-normalized-surname>PATNAIK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1928</xocs:ref-first-fp>
            <xocs:ref-last-lp>1940</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0175">
            <xocs:ref-normalized-surname>TOMITA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>22</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0180">
            <xocs:ref-normalized-surname>YANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>3386</xocs:ref-first-fp>
            <xocs:ref-last-lp>3395</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0185">
            <xocs:ref-normalized-surname>ITO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>352</xocs:ref-first-fp>
            <xocs:ref-last-lp>357</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0190">
            <xocs:ref-normalized-surname>YUZO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1674</xocs:ref-first-fp>
            <xocs:ref-last-lp>1679</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0195">
            <xocs:ref-normalized-surname>BELLON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>2439</xocs:ref-first-fp>
            <xocs:ref-last-lp>2450</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0200">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1243</xocs:ref-first-fp>
            <xocs:ref-last-lp>1255</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0205">
            <xocs:ref-normalized-surname>JASMINE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>929</xocs:ref-first-fp>
            <xocs:ref-last-lp>946</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0210">
            <xocs:ref-normalized-surname>KRUEGER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>3933</xocs:ref-first-fp>
            <xocs:ref-last-lp>3939</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0215">
            <xocs:ref-normalized-surname>SAITOH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>716</xocs:ref-first-fp>
            <xocs:ref-last-lp>727</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0220">
            <xocs:ref-normalized-surname>HIAKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>402</xocs:ref-first-fp>
            <xocs:ref-last-lp>415</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0225">
            <xocs:ref-normalized-surname>MACAIRE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>21357</xocs:ref-first-fp>
            <xocs:ref-last-lp>21370</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0230">
            <xocs:ref-normalized-surname>TANAKANAKANISHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>188</xocs:ref-first-fp>
            <xocs:ref-last-lp>200</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0235">
            <xocs:ref-normalized-surname>TOMOHIRO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>27645</xocs:ref-first-fp>
            <xocs:ref-last-lp>27655</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0240">
            <xocs:ref-normalized-surname>TOMOHIRO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>791</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0245">
            <xocs:ref-normalized-surname>TSUMURAYA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>713</xocs:ref-first-fp>
            <xocs:ref-last-lp>722</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0250">
            <xocs:ref-normalized-surname>KOZAKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>442</xocs:ref-first-fp>
            <xocs:ref-last-lp>460</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0255">
            <xocs:ref-normalized-surname>MOLES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>121</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0260">
            <xocs:ref-normalized-surname>NAOKO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>87</xocs:ref-first-fp>
            <xocs:ref-last-lp>97</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0265">
            <xocs:ref-normalized-surname>TOMOHIRO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>2044</xocs:ref-first-fp>
            <xocs:ref-last-lp>2055</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0270">
            <xocs:ref-normalized-surname>WOO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>626</xocs:ref-first-fp>
            <xocs:ref-last-lp>635</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0275">
            <xocs:ref-normalized-surname>RAJNEELA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-article-number>e71672</xocs:ref-article-number>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0280">
            <xocs:ref-normalized-surname>MALLICK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>709</xocs:ref-first-fp>
            <xocs:ref-last-lp>719</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0285">
            <xocs:ref-normalized-surname>GEORGES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>3770</xocs:ref-first-fp>
            <xocs:ref-last-lp>3777</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0290">
            <xocs:ref-normalized-surname>UTANIGUCHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>183</xocs:ref-first-fp>
            <xocs:ref-last-lp>189</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0295">
            <xocs:ref-normalized-surname>GUIMARAESCORREA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1041</xocs:ref-first-fp>
            <xocs:ref-last-lp>1058</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0300">
            <xocs:ref-normalized-surname>ISHITSUKA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>218</xocs:ref-first-fp>
            <xocs:ref-last-lp>225</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0305">
            <xocs:ref-normalized-surname>XU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>5</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0310">
            <xocs:ref-normalized-surname>ELHAJJ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>2072</xocs:ref-first-fp>
            <xocs:ref-last-lp>2080</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0315">
            <xocs:ref-normalized-surname>JU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>43</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0320">
            <xocs:ref-normalized-surname>BAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>117</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0325">
            <xocs:ref-normalized-surname>HAMASAKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>2241</xocs:ref-first-fp>
            <xocs:ref-last-lp>2248</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0330">
            <xocs:ref-normalized-surname>ISHIKAWA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>879</xocs:ref-first-fp>
            <xocs:ref-last-lp>887</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0335">
            <xocs:ref-normalized-surname>HSATOMI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>3575</xocs:ref-first-fp>
            <xocs:ref-last-lp>3584</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0340">
            <xocs:ref-normalized-surname>NARITA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1114</xocs:ref-first-fp>
            <xocs:ref-last-lp>1124</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0345">
            <xocs:ref-normalized-surname>BLEUMINK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>362</xocs:ref-first-fp>
            <xocs:ref-last-lp>370</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sbref0350">
            <xocs:ref-normalized-surname>HOUSSEIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>117639</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>HOUSSEINX2020X1189</xocs:refkey3>
         <xocs:refkey4lp>HOUSSEINX2020X1189X1197</xocs:refkey4lp>
         <xocs:refkey4ai>HOUSSEINX2020X1189XM</xocs:refkey4ai>
         <xocs:refkey5>HOUSSEINX2020X1189X1197XM</xocs:refkey5>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2021-07-23T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2021-07-23T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2020 Elsevier Ltd. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S1359-6446(20)30172-0</xocs:pii-formatted>
         <xocs:pii-unformatted>S1359644620301720</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S1359644620301720</xocs:eid>
         <xocs:doi>10.1016/j.drudis.2020.04.023</xocs:doi>
         <xocs:cid>271275</xocs:cid>
         <xocs:timestamp>2021-01-30T05:30:23.899605Z</xocs:timestamp>
         <xocs:cover-date-start>2020-07-01</xocs:cover-date-start>
         <xocs:cover-date-end>2020-07-31</xocs:cover-date-end>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S1359644620301720-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620301720/MAIN/application/pdf/509f8f3a40051aaaee6f8ac3a5338fac/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>1342612</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>9</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S1359644620301720-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620301720/PREVIEW/image/png/f69fd153766e489520ca5735f9d0e7b7/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>92625</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620301720-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620301720/gr1/DOWNSAMPLED/image/jpeg/f3de99ddb259448c3ce439710b6e9346/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>107875</xocs:filesize>
               <xocs:pixel-height>863</xocs:pixel-height>
               <xocs:pixel-width>836</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620301720-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620301720/gr2/DOWNSAMPLED/image/jpeg/777bc338d2205d4a7275d25952bd2574/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>103666</xocs:filesize>
               <xocs:pixel-height>800</xocs:pixel-height>
               <xocs:pixel-width>837</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620301720-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620301720/gr1/THUMBNAIL/image/gif/4a805cfed50f07656558f5d865f30487/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9535</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>159</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620301720-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620301720/gr2/THUMBNAIL/image/gif/c5029703acf422435e3ca93052f3bf2d/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8681</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>171</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620301720-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620301720/gr1/HIGHRES/image/jpeg/dd08beec4c0a76729734be25a2ff97e3/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>995088</xocs:filesize>
               <xocs:pixel-height>3822</xocs:pixel-height>
               <xocs:pixel-width>3703</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620301720-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644620301720/gr2/HIGHRES/image/jpeg/511b95b7678433e4370a84456eeb7129/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>887097</xocs:filesize>
               <xocs:pixel-height>3540</xocs:pixel-height>
               <xocs:pixel-width>3704</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644620301720-am.pdf</xocs:attachment-eid>
               <xocs:file-basename>am</xocs:file-basename>
               <xocs:filename>am.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:filesize>765094</xocs:filesize>
               <xocs:attachment-type>AAM-PDF</xocs:attachment-type>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:10QR4TL7S59/MAIN/application/pdf/5bd2c1292bd78db01d856b5a84b4adb5/am.pdf</xocs:ucs-locator>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" version="5.6" xml:lang="en" docsubtype="fla">
         <item-info>
            <jid>DRUDIS</jid>
            <aid>2685</aid>
            <ce:pii>S1359-6446(20)30172-0</ce:pii>
            <ce:doi>10.1016/j.drudis.2020.04.023</ce:doi>
            <ce:copyright type="full-transfer" year="2020">Elsevier Ltd</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig0005">
               <ce:label>Figure 1</ce:label>
               <ce:caption id="cap0005">
                  <ce:simple-para id="spar0005" view="all">Apoptosis pathways in normal cells and in human T cell lymphotropic virus-1 (HTLV-1)-infected T cells. <ce:bold>(a)</ce:bold> (i) Extrinsic apoptotic signaling pathway; (ii) intrinsic apoptotic signaling pathway. These pathways converge at the activation of caspases. <ce:bold>(b)</ce:bold> Inhibition of apoptosis pathways in adult T cell leukemia (ATL) cells. (i) The extrinsic pathway of apoptosis has multiple sites of suppression whereby Tax upregulates c-FLIP, which inhibits FADD and procaspase 8. A20 is upregulated by Tax and inhibits the interaction between FADD and caspase 8. The downregulation of ERG3 by Tax inhibits FAS. Hypermethylation of <ce:italic>DAPK</ce:italic> causes its silencing and inhibits caspases 3, 6, and 7. Tax upregulates XIAP and cIAP, whereas HBZ enhances Survivin. (ii) In the intrinsic apoptotic pathway, Tax upregulates the antiapoptotic proteins Bcl-2 and Bcl-xL and downregulates the proapoptotic protein Bax. Tax induces the secretion of cytokines allowing STAT3 activation and subsequent upregulation of proapoptotic proteins, interacts with TRAF6, an Mcl-1 inhibitor, and inhibits cytochrome c release from the mitochondria. HBZ upregulates Bcl-2 and interacts with FOXO3 to inhibit Bim. The overall result of these effects is the inhibition of apoptosis. For definitions of abbreviations, please see the main text.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0005" role="short">Figure 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S1359644620301720/gr1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig0010">
               <ce:label>Figure 2</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="spar0010" view="all">Deregulation of proliferative pathways in human T cell lymphotropic virus-1 (HTLV-1)-infected T-cells. <ce:bold>(a)</ce:bold> Activation of the nuclear factor kappa B (NF-κB) pathway by Tax. Tax activates IKK directly by interaction with NEMO or indirectly by interacting with NIK and MEKK. The activated IKK complex phosphorylates IκB, which cause its proteasomal degradation. Tax also inhibits the interaction between IκB and NF-κB. The free members of NF-κB translocate to the nucleus and activate the NF-κB target genes. In the nucleus, Tax interacts with a transcriptional coactivator, which enhance gene expression. <ce:bold>(b)</ce:bold> Tax and HBZ effects on the phosphatidylinositol 3-kinase (PI3K)-AKT pathway. Activation of PI3K by Tax generates phosphatidylinositol-3,4,5-triphosphate (PIP3), which activates AKT and its downstream effector mammalian target of rapamycin (mTOR), which in turn activates many proteins involved in enhancing the expression of proliferation-related genes. Tax inhibits PHLPP and PTEN causing the suppression of PI3K inhibition, and HBZ interacts with GADD34 to suppress mTOR inactivation. <ce:bold>(c)</ce:bold> Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathay activation in HTLV-1 cells. Given the phosphorylation of JAKs by Tax, STATs become activated and translocate to the nucleus to activate their corresponding target genes. For additional definitions of abbreviations, please see the main text.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0010" role="short">Figure 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S1359644620301720/gr2" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl0005" frame="topbot" rowsep="0" colsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="spar0015" view="all">ATL classification and criteria</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0015" role="short">Table 1</ce:alt-text>
               <tgroup cols="6">
                  <colspec colname="col1"/></colspec>
                  <colspec colname="col2"/></colspec>
                  <colspec colname="col3"/></colspec>
                  <colspec colname="col4"/></colspec>
                  <colspec colname="col5"/></colspec>
                  <colspec colname="col6"/></colspec>
                  <thead valign="top">
                     <row rowsep="1">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Subtype</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">% of patients</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Average survival time</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Hypercalcemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">LDH</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">% Leukemic cells</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Acute</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">60%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6 months</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Yes</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">High</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">High</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Lymphoma</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">20%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10 months</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Yes</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">High</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Absent</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Chronic</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">24 months</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">No</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">> Normal</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Rare</entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" role="rowhead" align="left">Smoldering</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15%</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Years</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">No</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">> Normal</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Rare</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl0010" frame="topbot" rowsep="0" colsep="0">
               <ce:label>Table 2</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="spar0020" view="all">Mechanisms of action of preclinical drugs that target ATL, indicating the pathway and specific target for each drug</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="at0020" role="short">Table 2</ce:alt-text>
               <tgroup cols="4">
                  <colspec colname="col1"/></colspec>
                  <colspec colname="col2"/></colspec>
                  <colspec colname="col3"/></colspec>
                  <colspec colname="col4"/></colspec>
                  <thead valign="top">
                     <row rowsep="1">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pathway</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Compound</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Specific target in the pathway</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Refs</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="6" role="rowhead rowgroup">PI3K/AKT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">LY294002</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AKT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0005" refid="bib0125">[25]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Idelalisib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AKT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0010" refid="bib0130">[26]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Rapamycin</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">mTOR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0015" refid="bib0135">[27]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">NVP-BEZ235</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">mTOR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0020" refid="bib0140">[28]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Everolimus</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">mTORC1/2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0025" refid="bib0145">[29]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Torin2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">mTOR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0030" refid="bib0150">[30]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Celecoxib</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Cox-2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0035" refid="bib0155">[31]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="6" role="rowhead rowgroup">JAK-STAT</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">AG490</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0040" refid="bib0175">[35]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">AZ960</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0045" refid="bib0180">[36]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Deguelin</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">STAT3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0050" refid="bib0185">[37]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Resveratrol</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">STAT3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0055" refid="bib0190">[38]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">BNZ-1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IL-2, IL-15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0060" refid="bib0200">[40]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">SMI-4a</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pim1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0065" refid="bib0195">[39]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">AZD1208</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Pim1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0070" refid="bib0195">[39]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="15" role="rowhead rowgroup">NF-κB</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Cyclopentenone</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IKK-β</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0075" refid="bib0030">[6]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Sodium salicylate</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IKK-β</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0080" refid="bib0030">[6]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Peridinin</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IKK-α, IKK-β</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0085" refid="bib0035">[7]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Butein</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IKK-α, IKK-β</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0090" refid="bib0040">[8]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Fucoxanthin</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IκB-α</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0095" refid="bib0045">[9]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">NIK-333</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IκB-α</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0100" refid="bib0050">[10]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Bay 11-7082</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IκB-α</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0105" refid="bib0055">[11]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Propolis</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IκB-α</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0110" refid="bib0060">[12]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">I3C</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IκB-α</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0115" refid="bib0065">[13]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Am80</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">IκB-α</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0120" refid="bib0070">[14]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">DHMEQ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">p65</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0125" refid="bib0080">[16]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Fludarabine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Nuclear translocation</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0130" refid="bib0085">[17]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">OkA</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PP2A</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0135" refid="bib0090">[18]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Geldanamycin</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Hsp90</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0140" refid="bib0095">[19]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">AUY922</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Hsp90</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0145" refid="bib0100">[20]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Ritonavir</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">HIV protease inhibitor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0150" refid="bib0105">[21]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" valign="middle" morerows="22" role="rowhead rowgroup">Apoptosis</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">STF-62247/ NCO-90/141</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Caspase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-refs id="crfs0005" refid="bib0235 bib0240">[47,48]</cross-refs>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Hippuristanol</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">caspase-3, 8, and 9; c-FLIP, XIAP</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0155" refid="bib0245">[49]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Telmisartan</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Caspase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0160" refid="bib0250">[50]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">NSC 19630/ 617145</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">WRN helicase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0165" refid="bib0255">[51]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Phx-3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Fas, caspase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0170" refid="bib0260">[52]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Sirtinol</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SIRT1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0175" refid="bib0265">[53]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">DHURS</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Caspases 9,3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0180" refid="bib0270">[54]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">F2 of Sesbania grandiflora</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Proapoptotic proteins/cytochrome release</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0185" refid="bib0275">[55]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">COR-D</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AIFs</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0190" refid="bib0280">[56]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">EAPB0203</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">c-IAP-1, Bcl-X<inf loc="post">L</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0195" refid="bib0285">[57]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">13-cis-retinoic acid</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Thioredoxin</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0200" refid="bib0290">[58]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">C7a</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Cytochrome c release</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0205" refid="bib0295">[59]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Hypericin</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Tax/HBZ</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0210" refid="bib0305">[61]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">9AA</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">p53</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0215" refid="bib0315">[63]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">PJ-34</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PARP-1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0220" refid="bib0320">[64]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">TMNAA</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CDK4/RB</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0225" refid="bib0325">[65]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Honokiol</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Cyclins and CDK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0230" refid="bib0330">[66]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">NK314</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Top2α</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0235" refid="bib0335">[67]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">BAY 1143572</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CDK9/P-TEFb</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0240" refid="bib0340">[68]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">ST1926</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Tax and P53</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0245" refid="bib0310">[62]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">ABT-737</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Bcl2, Bcl-xL /Bcl-w</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0250" refid="bib0300">[60]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Rocaglamide</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">c-FLIP</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0255" refid="bib0345">[69]</cross-ref>
                        </entry>
                     </row>
                     <row>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left" role="rowhead">Thymoquinone</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Bcl-2, Bax, p53</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <cross-ref id="crf0260" refid="bib0350">[70]</cross-ref>
                        </entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="doh0005">
               <ce:textfn>Review</ce:textfn>
               <ce:dochead id="doh0010">
                  <ce:textfn>Gene to screen</ce:textfn>
               </ce:dochead>
            </ce:dochead>
            <ce:title id="tit0005">Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside</ce:title>
            <ce:author-group id="aug0005">
               <ce:author id="aut0005" author-id="S1359644620301720-f2ca31054e1c3277275835a2186cdc2d">
                  <ce:given-name>Marwa</ce:given-name>
                  <ce:surname>Houssein</ce:surname>
                  <ce:cross-ref id="crf0265" refid="aff0005">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0270" refid="aff0010">
                     <ce:sup loc="post">2</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="aut0010" orcid="0000-0001-7629-4357" author-id="S1359644620301720-276927496216f027f730fd3024b3ecbf">
                  <ce:given-name>Mahmoud</ce:given-name>
                  <ce:surname>Khalil</ce:surname>
                  <ce:cross-ref id="crf0275" refid="aff0005">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="aut0015" author-id="S1359644620301720-9ce11ad12b3619dfbdbb483445346dc4">
                  <ce:given-name>Maamoun</ce:given-name>
                  <ce:surname>Fatfat</ce:surname>
                  <ce:cross-ref id="crf0280" refid="aff0010">
                     <ce:sup loc="post">2</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="aut0020" author-id="S1359644620301720-4d365958f2ff4bfd641de579980d2cfd">
                  <ce:given-name>Hala</ce:given-name>
                  <ce:surname>Gali-Muhtasib</ce:surname>
                  <ce:cross-ref id="crf0285" refid="aff0010">
                     <ce:sup loc="post">2</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0290" refid="aff0015">
                     <ce:sup loc="post">3</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crf0295" refid="cor0005">
                     <ce:sup loc="post">⁎</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff0005" affiliation-id="S1359644620301720-343fb8416a302eda4e5ad6ba9e8f91c1">
                  <ce:label>1</ce:label>
                  <ce:textfn>Department of Biological Sciences, Faculty of Science, Beirut Arab University, Lebanon</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Biological Sciences</sa:organization>
                     <sa:organization>Faculty of Science</sa:organization>
                     <sa:organization>Beirut Arab University</sa:organization>
                     <sa:country>Lebanon</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="sot0005">Department of Biological Sciences, Faculty of Science, Beirut Arab University, Lebanon</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0010" affiliation-id="S1359644620301720-a4fb56c098654519d4dfeaea22b55c45">
                  <ce:label>2</ce:label>
                  <ce:textfn>Center for Drug Discovery, American University of Beirut, Lebanon</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Center for Drug Discovery</sa:organization>
                     <sa:organization>American University of Beirut</sa:organization>
                     <sa:country>Lebanon</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="sot0010">Center for Drug Discovery, American University of Beirut, Lebanon</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff0015" affiliation-id="S1359644620301720-54061364dadbb35192df8793b382f8ba">
                  <ce:label>3</ce:label>
                  <ce:textfn>Department of Biology, American University of Beirut, Lebanon</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Biology</sa:organization>
                     <sa:organization>American University of Beirut</sa:organization>
                     <sa:country>Lebanon</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="sot0015">Department of Biology, American University of Beirut, Lebanon</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor0005">
                  <ce:label>⁎</ce:label>
                  <ce:text>
                     <ce:italic>Corresponding author</ce:italic>:</ce:text>
               </ce:correspondence>
            </ce:author-group>
            
            <ce:abstract id="abs0010" view="all" class="author"><ce:abstract-sec id="abst0010" view="all">
                  <ce:simple-para id="spar0030" view="all">Human T cell lymphotropic virus-1 (HTLV-1) is the causative agent of adult T cell leukemia (ATL), an aggressive malignancy of mature activated T cells. Although many therapeutic strategies are available, none are effective and most patients experience recurrence of the disease. Over the past decade, many drugs have been discovered that showed promising therapeutic potential against ATL but which remain in the preclinical testing phase. Mechanistically, these drugs either induce apoptosis or regulate cellular proliferation in ATL cells. Here, we provide a summary of these promising drugs that target ATL, with a focus on their mechanism of anticancer activity, to offer insights into the use of multiple drugs with different targets for enhancing ATL eradication.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec0005" role="introduction" view="all">
                  <ce:section-title id="sect0010">Introduction</ce:section-title>
                  <ce:para id="par0020" view="all">Cancer is one of the most challenging diseases and a major leading cause of death. In 2018, the International Agency for Research on Cancer (IARC) released the latest global cancer data in which the cancer burden was reported to reach 18.1 million new cases with 9.6 million cancer deaths. In 1980, a link between cancer and retroviruses was described with evidence showing that HTLV-1 increases the risk of ATL <ce:cross-ref id="crf0300" refid="bib0005">[1]</ce:cross-ref>. HTLV-1 is an endemic retrovirus most common in southwestern Japan, the Caribbean Islands, Central and South America, intertropical Africa, Iran, and the Middle East.</ce:para>
                  <ce:para id="par0025" view="all">ATL is a rare and aggressive malignancy of regulatory T cells (Tregs), which exhibits many abnormalities at different levels, including gains and losses in different chromosomes, such as 14q and 13q, respectively, in addition to epigenetic modifications marked by DNA hypermethylation at different loci <ce:cross-ref id="crf0305" refid="bib0005">[1]</ce:cross-ref>. Current treatment options for HTLV-1-induced ATL are unsatisfactory and show chemoresistance with severe immunosuppression. New agents evolving from research could change the treatment landscape and lead to the discovery of effective therapeutics against ATL. Here, we highlight recent discoveries and the most effective drugs against ATL currently at the preclinical stage, focusing on their mechanisms for targeting the apoptotic and proliferative signaling pathways.</ce:para>
               </ce:section>
               <ce:section id="sec0010" view="all">
                  <ce:section-title id="sect0015">Apoptosis and cancer</ce:section-title>
                  <ce:para id="par0030" view="all">Our body generates ∼60 billion cells per day and eliminates billions of unwanted cells via apoptosis to maintain cellular homeostasis. Apoptosis is the most important mechanism of programmed cell death, which ensures a balance between cell death and cell proliferation <ce:cross-ref id="crf0310" refid="bib0010">[2]</ce:cross-ref>. <ce:cross-ref id="crf0315" refid="fig0005">Figure 1</ce:cross-ref>
                     <ce:float-anchor refid="fig0005"/></ce:float-anchor> represents the extrinsic and the intrinsic mechanisms of apoptosis.</ce:para>
                  <ce:para id="par0035" view="all">One main hallmark of cancer is the accumulation of mutations in genes involved in apoptosis that protect cancer cells from death, thus causing tumor growth. Cancer cells evade cell death through the inhibition of the intrinsic or extrinsic pathways of apoptosis. Overall, malignant cancer cells have an antiapoptotic phenotype with low levels of proapoptotic proteins. More than 50% of cancers harbor defects in the p53 tumor suppressor gene and several cancer types overexpress the inhibitors of apoptosis proteins (IAP), Survivin and Apollon. The impairment of the function of death receptors and the downregulation of surface receptors have been detected in leukemia and neuroblastoma cells <ce:cross-ref id="crf0320" refid="bib0015">[3]</ce:cross-ref>.</ce:para>
               </ce:section>
               <ce:section id="sec0015" view="all">
                  <ce:section-title id="sect0020">HTLV: the causative agent of ATL</ce:section-title>
                  <ce:para id="par0040" view="all">Oncoviruses block apoptosis and cause permanent infection, which leads to oncogenesis. One such oncovirus is HTLV-1, a complex retrovirus comprising a positive single-stranded RNA flanked by two long terminal repeats (LTRs) at the 5′ and 3′ regions. The genome of this virus is divided into structural genes: the group specific antigen (<ce:italic>Gag</ce:italic>), the protease gene (<ce:italic>pro</ce:italic>), the polymerase gene (<ce:italic>pol</ce:italic>), and the envelope gene (<ce:italic>env</ce:italic>), and regulatory genes (<ce:italic>pX</ce:italic> region located between <ce:italic>env</ce:italic> and 3′-LTR). Similar to other viruses, <ce:italic>gag</ce:italic> encodes the virion core protein and <ce:italic>pol</ce:italic> for reverse transcription, integrase, and protease functions. The <ce:italic>pX</ce:italic> region encodes the viral regulatory genes <ce:italic>tax</ce:italic>, <ce:italic>rex, p13, p30, p12</ce:italic>, and <ce:italic>p8</ce:italic> in addition to HTLV-1 basic zipper factor (<ce:italic>HBZ)</ce:italic>, an antisense transcript encoded by the minus strand of <ce:italic>pX</ce:italic>. These proteins have crucial roles during HTLV-1 infection and are responsible for the viral pathogenicity.</ce:para>
                  <ce:para id="par0045" view="all">There is an estimated 5 million–20 million individuals with HTLV-1 worldwide who are asymptomatic carriers; their lifetime risk of developing ATL is 3–5% after initial HTLV-1 infection, which occurs, in most cases, following breast feeding. ATL occurs following a latency period of >30 years. Based on Shimoniya classification, four subtypes of HTLV-1-induced ATL are distinguished <ce:cross-ref id="crf0325" refid="bib0020">[4]</ce:cross-ref>, which differ in their clinical presentation and outcome (<ce:cross-ref id="crf0330" refid="tbl0005">Table 1</ce:cross-ref>
                     <ce:float-anchor refid="tbl0005"/></ce:float-anchor>).</ce:para>
               </ce:section>
               <ce:section id="sec0020" view="all">
                  <ce:section-title id="sect0025">Targeted chemotherapy for ATL: promising preclinical drugs</ce:section-title>
                  <ce:para id="par0050" view="all">A range of preclinical drugs repress the proliferation pathways or activate apoptosis in HTLV-1-infected ATL cells. <ce:cross-ref id="crf0335" refid="tbl0010">Table 2</ce:cross-ref>
                     <ce:float-anchor refid="tbl0010"/></ce:float-anchor> presents a list of these drugs with their corresponding targets. Here, we discuss the therapeutic potential of these drugs with focus on their mechanisms of anticancer activity.</ce:para>
                  <ce:section id="sec0025" view="all">
                     <ce:section-title id="sect0030">Targeting nuclear factor kappa beta</ce:section-title>
                     <ce:para id="par0055" view="all">Nuclear factor kappa beta (NF-κB) is a protein complex, which stimulates or regulates the transcription of >150 genes. The NF-κB family comprises five transcription factors, which share a conserved domain at their N-terminal known as the Rel homology domain (RHD) <ce:cross-ref id="crf0340" refid="bib0025">[5]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0060" view="all">HTLV-1-infected ATL cells exhibit constitutive activation of NF-κB pathways. <ce:cross-ref id="crf0345" refid="fig0010">Figure 2</ce:cross-ref>
                        <ce:float-anchor refid="fig0010"/></ce:float-anchor>a shows the deregulation of the NF-κB pathway in HTLV-1-infected T cells. The NF-κB pathway can be inhibited by targeting the IκB Kinase complex (IKK complex). The activation of the IKK complex is known to phosphorylate IκB, which leads to its subsequent degradation.</ce:para>
                     <ce:para id="par0065" view="all">Several drugs have been found to inhibit the NF-κB pathway and, thus, could treat ATL progression. The inhibitors of the NF-κB pathway can be divided into several groups depending on their activity and the proteins they target. They can inhibit IKK complex activation, the phosphorylation or the proteasome degradation of the inhibitors of NF-κB proteins (IκB-α), translocation of NF-κB into the nucleus, and/or the binding of NF-κB to DNA.</ce:para>
                     <ce:para id="par0070" view="all">Sodium salicylate and cyclopentenone prostaglandins [prostaglandin A1 and 15-deoxy-Δ(12,14)-prostaglandin J2] were shown to prevent the degradation of the NF-κB repressor, IκB-α, by directly inhibiting the activity of IKK-β, the kinase that phosphorylates IκB-α <ce:cross-ref id="crf0350" refid="bib0030">[6]</ce:cross-ref>. Peridinin is one of the most abundant carotenoids found in nature. It inhibited NF-κB activation by suppressing IKK activation through suppression of IKK-α and IKK-β phosphorylation <ce:cross-ref id="crf0355" refid="bib0035">[7]</ce:cross-ref>. Butein, a bioactive plant polyphenol, inhibited the phosphorylation of IKK-α and IKK-β, RelA, and the DNA-binding activity of NF-κB and activating protein-1 (AP-1), resulting in the inhibition of the NF-κB and AKT signaling pathways in HTLV-1-infected T cells <ce:cross-ref id="crf0360" refid="bib0040">[8]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0075" view="all">The phosphorylation of IκB also activates the NF-κB pathway. Carotenoids, such as fucoxanthin and its metabolite, fucoxanthinol, suppressed IκB-α phosphorylation, resulting in the inactivation of NF-κB <ce:cross-ref id="crf0365" refid="bib0045">[9]</ce:cross-ref>. NIK-333, a synthetic retinoid <ce:cross-ref id="crf0370" refid="bib0050">[10]</ce:cross-ref>, and Bay 11-7082, an anti-inflammatory compound, induced apoptosis of HTLV-1-infected T-cell lines via irreversible inhibition of IκB-α phosphorylation <ce:cross-ref id="crf0375" refid="bib0055">[11]</ce:cross-ref>. Propolis (PE), a natural product produced by honeybees, and caffeic acid phenyl ethyl ester (CAPE), a PE-active component, strongly inhibited the activation of NF-κB, by preventing the Tax-induced degradation of IκB-α <ce:cross-ref id="crf0380" refid="bib0060">[12]</ce:cross-ref>. Indole-3-carbinol (I3C), a naturally occurring component of Brassicaceae, such as Brussels sprout, broccoli, and cabbage, also suppressed IκB-α phosphorylation and JunD expression, resulting in inactivation of NF-κB and AP-1 <ce:cross-ref id="crf0385" refid="bib0065">[13]</ce:cross-ref>. Retinoids are compounds that bind to and activate retinoic acid receptors (RARα, β, and γ and RXRα, β, and γ), members of the nuclear hormone receptor superfamily. Am80 (tamibarotene) is an RARα- and RARβ-specific ligand that significantly inhibited the phosphorylation of IκBα and NF-κB–DNA binding in ATL cells <ce:cross-ref id="crf0390" refid="bib0070">[14]</ce:cross-ref>. Another retinoid, all-<ce:italic>trans</ce:italic> retinoic acid (ATRA), inhibited the growth in HTLV-1-positive T cell lines via inhibition of NF-κB <ce:cross-ref id="crf0395" refid="bib0075">[15]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0080" view="all">The nuclear translocation of NF-κB members also could be inhibited. Dehydroxymethylepoxyquinomicin, (DHMEQ; isolated from <ce:italic>Amicolatopsis</ce:italic> sp.) blocked the nuclear translocation of p65 into the nucleus <ce:cross-ref id="crf0400" refid="bib0080">[16]</ce:cross-ref>. Fludarabine, a purine analog, inhibited the nuclear translocation of NF-κB and NF-κB–DNA-binding activity in ATL cells <ce:cross-ref id="crf0405" refid="bib0085">[17]</ce:cross-ref>. Additional compounds have other targets, such as PP2A (an inhibitor of the IKK complex) or heat shock protein 90 (Hsp90). Okadaic acid (OkA), cytostatin, and rubratoxin A are potent inhibitors of PP2A. OKA decreased the expression levels of cyclin D2, cyclin-dependent kinase 4, and cyclin-dependent kinase 6, and upregulation of p21, p27, and growth arrest and DNA-damage-inducible alpha (GADD45α) <ce:cross-ref id="crf0410" refid="bib0090">[18]</ce:cross-ref>. Geldanamycin (GA) is a benzoquinone antineoplastic antibiotic that specifically inhibited Hsp90 which resulted in IKK and NIK degradation and, thus, inactivation of the NF-κB pathway <ce:cross-ref id="crf0415" refid="bib0095">[19]</ce:cross-ref>. AUY922, a second-generation synthetic HSP90 inhibitor <ce:cross-ref id="crf0420" refid="bib0100">[20]</ce:cross-ref>, had a similar effect. Exposure of a HTLV-1-infected T cell line to ritonavir, an HIV protease inhibitor, induced apoptosis and inhibited the transcriptional activation of NF-κB in these cells <ce:cross-ref id="crf0425" refid="bib0105">[21]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0085" view="all">Collectively, the literature shows that the suppression of the NF-<ce:italic>κ</ce:italic>B pathway could be one of the most effective and promising mechanisms for specifically inhibiting ATL cells, given that this pathway is required for the development of HTLV-1-transformed cells. Thus, further development and clinical translation of the above-mentioned drugs that target NF-κB are warranted.</ce:para>
                  </ce:section>
                  <ce:section id="sec0030" view="all">
                     <ce:section-title id="sect0035">Targeting PI3K/AKT cascade</ce:section-title>
                     <ce:para id="par0090" view="all">The phosphatidylinositol 3-kinase (PI3K) serine/threonine kinase AKT (also known as PKB) pathway has a crucial role in regulating diverse cellular functions, including apoptosis.</ce:para>
                     <ce:para id="par0095" view="all">The most important function of activated PI3K is the phosphorylation of phosphatidylinositol lipids, which results in the production of phosphatidylinositol-3,4,5-triphosphate (PIP3) and phosphatidylinositol-4,5-bisphosphate (PIP2), the regulators of many signaling proteins located downstream of PI3K. Binding of PIP2 and PIP3 to the pleckstrin homology (PH) domain of AKT causes the translocation of AKT to the plasma membrane <ce:cross-ref id="crf0430" refid="bib0110">[22]</ce:cross-ref>, which in turn phosphorylates a range of proteins, such as caspase 9, mouse double minute 2 homolog (MDM2), forkhead box protein O1 (FOXO1), BCL2-associated agonist of cell death (BAD), and glycogen synthase kinase 3 beta (GSK-3β), generating overall proliferative signals and antiapoptotic effects. AKT also activates mammalian target of rapamycin (mTOR) kinase, which exists in two functional complexes: mTOR complex 1(mTORC1) and mTOR complex 2 (mTORC2) <ce:cross-ref id="crf0435" refid="bib0115">[23]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0100" view="all">The PI3K/AKT pathway is constitutively activated in ATL cells (<ce:cross-ref id="crf0440" refid="fig0010">Fig. 2</ce:cross-ref>b), mainly because of phosphatase and tensin homolog (PTEN) inactivation, a tumor suppressor that dephosphorylates PIP3 <ce:cross-ref id="crf0445" refid="bib0120">[24]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0105" view="all">To inhibit the PI3K-AKT pathway, drugs can either target AKT phosphorylation or mTOR. Drugs that target AKT include LY294002 and idelalisib. LY294002, a morpholino derivative of quercetin, induced apoptosis and AKT dephosphorylation in ATL cell lines <ce:cross-ref id="crf0450" refid="bib0125">[25]</ce:cross-ref>. C-C motif chemokine 22 (CCL22) promotes survival of ATL cells through the PI3K-AKT pathway, whereas idelalisib blocked this CCL22-induced phosphorylation of AKT and significantly inhibited the proliferation of ATL cells <ce:cross-ref id="crf0455" refid="bib0130">[26]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0110" view="all">Rapamycin, NVP-BEZ235, everolimus, and Torin2 are mTOR inhibitors. Rapamycin caused G1 phase arrest and inhibited the growth of HTLV-1-infected cell lines <ce:cross-ref id="crf0460" refid="bib0135">[27]</ce:cross-ref>. NVP-BEZ235 is an imidazo[4,5-c] quinoline derivative that suppressed the PI3K and mTORC2 pathways in ATL cells <ce:cross-ref id="crf0465" refid="bib0140">[28]</ce:cross-ref>. Everolimus (RAD001), a macrolide antibiotic derived from rapamycin, induced the degradation of Tax and the inhibition of mTOR <ce:cross-ref id="crf0470" refid="bib0145">[29]</ce:cross-ref>. Torin2 is a second-generation ATP-competitive inhibitor of the mTOR. Torin2 induced cell growth inhibition associated with a strong reduction of phosphorylated AKT, a downstream effector of mTORC2. In ATL cells, Torin2 was able to inhibit both mTORC1 and mTORC2 <ce:cross-ref id="crf0475" refid="bib0150">[30]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0115" view="all">Celecoxib is a nonsteroidal anti-inflammatory drug that is a selective inhibitor of cyclooxegenase-2 (Cox-2), a family of enzymes involved in the proliferation and angiogenesis of many tumors. Celecoxib was shown to induce disruption of the AKT signaling pathway <ce:cross-ref id="crf0480" refid="bib0155">[31]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0120" view="all">The above preclinical drugs could become effective therapeutics against ATL because they inhibit key molecules of the PI3K/AKT signaling pathway, such as tenalisib and copanlisib and the AKT inhibitor MK-2206 <ce:cross-ref id="crf0485" refid="bib0160">[32]</ce:cross-ref>, which are in clinical trials. The PI3K inhibitors tenalisib (RP6530) <ce:cross-ref id="crf0490" refid="bib0165">[33]</ce:cross-ref> and copanlisib (BAY 80-6946) <ce:cross-ref id="crf0495" refid="bib0170">[34]</ce:cross-ref> were evaluated for T cell lymphoma treatment and showed a response rate of 45% and 50%, respectively. The AKT inhibitor MK-2206 was also evaluated in a Phase II trial in patients with refractory lymphoma and showed an overall response rate of 14% in different lymphoma types <ce:cross-ref id="crf0500" refid="bib0160">[32]</ce:cross-ref>.</ce:para>
                  </ce:section>
                  <ce:section id="sec0035" view="all">
                     <ce:section-title id="sect0040">Targeting JAK-STAT pathway</ce:section-title>
                     <ce:para id="par0125" view="all">The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is responsible for cellular responses to cytokines, namely interferons and interleukins (ILs). The phosphorylation of JAKs leads to their activation and, thus, to the activation of STATs, which are then translocated to the nucleus, where they bind, as dimers or oligomers, the enhancer sequence of the target genes to regulate their transcription.</ce:para>
                     <ce:para id="par0130" view="all">The JAK/STAT pathway is constitutively activated in HTLV-1-transformed cells, which specifically show constitutive phosphorylation of JAK3 and STAT5. <ce:cross-ref id="crf0505" refid="fig0010">Figure 2</ce:cross-ref>c details the main players in the JAK/STAT pathway in HTLV-1 cells.</ce:para>
                     <ce:para id="par0135" view="all">The inhibition of the JAK/STAT pathway can be through JAK, STAT, or the degradation of ILs. AG490 and AZ960 are inhibitors of JAK. AG490 induced the G1 cell cycle arrest of ATL cells by apoptosis, in addition to the reduction of STAT5 activity <ce:cross-ref id="crf0510" refid="bib0175">[35]</ce:cross-ref>. AZ960, a novel inhibitor of JAK2 kinase, turned off the JAK2/STAT5 pathway, allowing the growth arrest and apoptosis induction of HTLV-1-infected T cells <ce:cross-ref id="crf0515" refid="bib0180">[36]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0140" view="all">Another target of the JAK/STAT pathway is STAT3. The naturally occurring rotenoid deguelin <ce:cross-ref id="crf0520" refid="bib0185">[37]</ce:cross-ref> and the polyphenolic compound resveratrol, found in the skin of red grapes, inhibited the phosphorylation of STAT3 <ce:cross-ref id="crf0525" refid="bib0190">[38]</ce:cross-ref> in HTLV-1-infected ATL cells. Pim1, a STAT3 downstream kinase effector, is overexpressed in HTLV-1-infected ATL cells. Inhibitors of Pim1, such as SMI-4a and AZD1208, triggered apoptosis in these cells <ce:cross-ref id="crf0530" refid="bib0195">[39]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0145" view="all">Inhibitors of ILs can induce the downregulation of the JAK/STAT pathway. BNZ-1 is a PEGylated peptide designed to specifically bind the γ-chain receptors to selectively block IL-2, IL-15, and IL-9 signaling. ATL is dependent on IL-2 and IL-15 for survival. Treatment of ATL with BNZ-1 reduced cytokine-mediated proliferation and viability <ce:cross-ref id="crf0535" refid="bib0200">[40]</ce:cross-ref>. These findings suggest that several preclinical drugs that mediate the death of ATL cells by suppressing the JAK/STAT pathway are relevant for translation to Phase I clinical trials. In fact, many promising drugs that are in advanced clinical testing phases are known to inhibit the JAK/STAT pathway. These include the JAK1/2 inhibitor ruxolitinib and the competitive inhibitor of the JAK family kinases, cerdulatinib, both of which displayed a 35–38% overall response rate in patients with T cell lymphoma <ce:cross-ref id="crf0540" refid="bib0205">[41]</ce:cross-ref>.</ce:para>
                  </ce:section>
                  <ce:section id="sec0040" view="all">
                     <ce:section-title id="sect0045">Targeting apoptosis pathways</ce:section-title>
                     <ce:para id="par0150" view="all">The main characteristic of HTLV-1-infected cells is their resistance to apoptosis. Tax and HBZ are two viral proteins responsible for the deregulation of apoptotic pathways (<ce:cross-ref id="crf0545" refid="fig0005">Fig. 1</ce:cross-ref>b). Deregulation of extrinsic apoptosis pathways involves high expression levels of cellular FLICE-like inhibitory protein (c-FLIP) in Tax-expressing cells, thus inhibiting Fas-associated protein with death domain (FADD), procaspase 8, and the death receptors CD95, TRAIL-1, and TRAIL-2 <ce:cross-ref id="crf0550" refid="bib0210">[42]</ce:cross-ref>. The tumor necrosis factor (TNF)-induced molecule A20 is also highly expressed in HTLV-1 cells and prevents caspase 8 recruitment to FADD <ce:cross-ref id="crf0555" refid="bib0215">[43]</ce:cross-ref>. The hypermethylation of the death-associated protein kinase (DAPK), an upstream regulator of caspases 3, 6, and 7, inhibits apoptosis in ATL cells <ce:cross-ref id="crf0560" refid="bib0220">[44]</ce:cross-ref>. Deregulation of intrinsic pathways involves Tax-induced high expression of Bcl-2, Mcl-1, and Bcl-xL, and downregulation of Bax <ce:cross-ref id="crf0565" refid="bib0225">[45]</ce:cross-ref>, whereas HBZ suppresses the expression of Bim, by targeting FoxO3a, a critical transcription factor for Bim <ce:cross-ref id="crf0570" refid="bib0230">[46]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0155" view="all">Many drugs induce apoptosis in ATL cells that are infected with HTLV-1. Caspases, anti- and proapoptotic proteins, as well as regulators of cell cycle and apoptosis and c-FLIP, could be targets of these drugs. STF-62247 <ce:cross-ref id="crf0575" refid="bib0235">[47]</ce:cross-ref> and NCO-90/141 <ce:cross-ref id="crf0580" refid="bib0240">[48]</ce:cross-ref> are small molecules that induce cell death by caspase-dependent and -independent mechanisms. Hippuristanol, a eukaryotic translation initiation inhibitor from the coral <ce:italic>Isis hippuris</ce:italic>, reduces the expression of Bcl-xL, cIAP2, XIAP, and c-FLIP, and activates caspases 3, 8, and 9 <ce:cross-ref id="crf0585" refid="bib0245">[49]</ce:cross-ref>. Telmisartan induces apoptosis in HTLV-1 cells via caspase activation <ce:cross-ref id="crf0590" refid="bib0250">[50]</ce:cross-ref>. NSC 19630 and NSC 617145 are Werner syndrome ATP-dependent helicase (WRN) inhibitors that cause disruption of the mitochondrial membrane potential, downregulation of Bcl-2, and activation of caspase-3-dependent apoptosis in ATL cells <ce:cross-ref id="crf0595" refid="bib0255">[51]</ce:cross-ref>. 2-Aminophenoxazine-3-one (Phx-3) upregulated the expression of FAS expression and activated caspases 8 and 9 in HTLV-1-positive leukemia cells <ce:cross-ref id="crf0600" refid="bib0260">[52]</ce:cross-ref>. SIRT, a NAD+-dependent histone/protein deacetylase, which is highly expressed in ATL cells, could be inhibited by the SIRT1 inhibitor sirtinol via activation of the caspase family and degradation of SIRT1 in the nucleus <ce:cross-ref id="crf0605" refid="bib0265">[53]</ce:cross-ref>. 2α,3α-Dihydroxyurs-12-en-28-oic acid (DHURS), purified from the dried spikes of <ce:italic>Prunella vulgaris</ce:italic>, also induced apoptosis via mitochondrial cytochrome c release, and subsequent activation of caspase 9 and 3, leading to the activation of caspases 7 and 8 <ce:cross-ref id="crf0610" refid="bib0270">[54]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0160" view="all">An extract of the Indian plant <ce:italic>Sesbania grandiflora</ce:italic> was shown to upregulate proapoptotic proteins and inhibit the expression of antiapoptotic proteins with the release of cytochrome c <ce:cross-ref id="crf0615" refid="bib0275">[55]</ce:cross-ref>. Corchorusin-D (COR-D), the active ingredient of the plant <ce:italic>Corchorus acutangulus</ce:italic> Lam, also has antileukemic activities. It caused apoptotic cell death via mitochondrial dysfunction and the release of apoptosis-inducing factors (AIFs). It also induced the translocation of Bax from the cytosol to the mitochondria, thus facilitating caspase 9 activation <ce:cross-ref id="crf0620" refid="bib0280">[56]</ce:cross-ref>. HTLV-1-infected cells treated with EAPB0203 showed significant downregulation of the antiapoptotic proteins cIAP-1 and Bcl-xL resulting in a significant loss of mitochondrial membrane potential, release of cytochrome c, and caspase-dependent apoptosis <ce:cross-ref id="crf0625" refid="bib0285">[57]</ce:cross-ref>. In HTLV-1(+) T cell lines, thioredoxin (TRX) is highly expressed, has an antiapoptotic function, promotes cell growth, and cooperates with the NADPH-TRX reductase system. Treatment of these cells with inhibitors of TRX reductase, 13-<ce:italic>cis</ce:italic>-retinoic acid (13-<ce:italic>cis</ce:italic>-RA) and azelaic acid, inhibited DNA synthesis <ce:cross-ref id="crf0630" refid="bib0290">[58]</ce:cross-ref>. In HTLV-1 cells, C7a, a bisphosphonic cyclopalladated complex, induced cytochrome c release from the mitochondria, caspase activation, nuclear condensation, and DNA degradation <ce:cross-ref id="crf0635" refid="bib0295">[59]</ce:cross-ref>. ABT-737 is an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, and exerted a synergistic effect along with bortezomib, a proteasome inhibitor, or suberoylanide hydroxamic acid (SAHA) and induced apoptosis in T cells infected with HTLV-1 <ce:cross-ref id="crf0640" refid="bib0300">[60]</ce:cross-ref>. Photodynamic therapy (PDT) selectively activates photosensitizers, such as the polycyclic quinone hypericin (HY), which is extracted from St John’s wort (<ce:italic>Hypericum perforatum</ce:italic> L.). Hypericin was shown to induce apoptosis in ATL cells mainly through mitochondrial-dependent apoptotic signaling. It also reduced the expression of Tax and HBZ by impairing HTLV-1 viral transcription through 5′-LTR and 3′-LTR <ce:cross-ref id="crf0645" refid="bib0305">[61]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0165" view="all">Regulators of cell cycle and apoptosis are targeted by different kinds of agent. The synthetic retinoid ST1926 induced apoptosis, DNA damage, upregulation of p53 proteins, and downregulation of Tax in HTLV-1-positive cells <ce:cross-ref id="crf0650" refid="bib0310">[62]</ce:cross-ref>. 9-Aminoacridine (9AA) is an aminoacridine in which the hydrogen at position 9 is replaced by an amino group. 9AA alone or in combination with campath-1H, a monoclonal antibody that binds to CD52 on the surface of mature lymphocytes, reactivated p53, causing apoptotic cell death. This combination also increased the proapoptotic protein Bax and cleavage of PARP <ce:cross-ref id="crf0655" refid="bib0315">[63]</ce:cross-ref>. PJ-34 is an inhibitor of PARP-1 that has been shown to induce cell cycle arrest and activate p53 and caspase-3-dependent apoptosis in cells infected with HTLV-1 <ce:cross-ref id="crf0660" refid="bib0320">[64]</ce:cross-ref>. The tetra methylnaphthalene derivative TMNAA was shown to selectively inhibit the proliferation of various HTLV-1-infected cells by increasing the population in G0/G1 phase and reducing that in S phase. TMNAA suppressed the phosphorylation of retinoblastoma protein and the expression of cyclin-dependent kinase 4 <ce:cross-ref id="crf0665" refid="bib0325">[65]</ce:cross-ref>. The Asian herbal tea, Honokiol, was also found to induce apoptosis in HTLV-1 infected ATL cells. Following treatment, cells were arrested in the G1 phase of the cell cycle because of the reduction in expression of cyclins D1, D2, E, CDK2, CDK4, and CDK6, and c-Myc. Apoptosis is induced by the reduction of cIAP-2, XIAP and survivin expression <ce:cross-ref id="crf0670" refid="bib0330">[66]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0170" view="all">NK314 is an anticancer agent with inhibitory activity specific for topoisomerase IIα (Top2α). In ATL cells, the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs) is highly expressed. NK314 was able to induce DNA double-strand breaks by inhibition of Top2α and the degradation of the catalytic subunit of DNA-PKcs <ce:cross-ref id="crf0675" refid="bib0335">[67]</ce:cross-ref>. The highly selective CDK9/P-TEFb inhibitor BAY 1143572 was shown to inhibit CDK9 and RNAPII CTD phosphorylation at serine 2 and to degrade c-Myc and Mcl-1, thus inducing apoptosis <ce:cross-ref id="crf0680" refid="bib0340">[68]</ce:cross-ref>.</ce:para>
                     <ce:para id="par0175" view="all">The downregulation of c-FLIP by rocaglamide (Roc) sensitizes CD95L- and TRAIL-induced apoptosis in HTLV-1-infected cells. By breaking TRAIL-R1/2 receptor resistance in ATL cells, rocaglamide induced apoptosis by inactivating translation initiation factor 4E (eIF4E), leading to the translational suppression of c-FLIP <ce:cross-ref id="crf0685" refid="bib0345">[69]</ce:cross-ref>. Curcumin, from turmeric (<ce:italic>Curcuma longa</ce:italic> L.), is known to inhibit many signaling pathways, including NF-κB, AP-1, JAK-STAT, and PI3K-Akt, in ATL cells. Thymoquinone extract from <ce:italic>Nigella sativa</ce:italic> has been shown to have potent apoptosis-inducing effects against ATL, particularly when combined with arsenic and interferon alpha <ce:cross-ref id="crf0690" refid="bib0350">[70]</ce:cross-ref>. By inducing apoptotic cell death, many preclinical drugs could reprogram cancer cells. forcing them onto a death pathway. This could help overcome one of the most important barriers facing ATL treatment.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec0045" view="all">
                  <ce:section-title id="sect0050">Concluding remarks</ce:section-title>
                  <ce:para id="par0180" view="all">In conclusion, many compounds, most of which are from herbal sources, have been shown to induce apoptosis or reduce cellular proliferation in ATL cells. Most of the compounds mentioned in this review have demonstrated high selectivity and effectiveness against ATL. More research is needed to translate these promising drugs to the clinical setting to investigate their ability to treat patients with ATL. Efforts should be directed towards combining multiple drugs with different molecular targets because this could offer the possibility of enhancing ATL eradication. The American Cancer Society declared that cancer death rates have dropped by 26% since 1991, and prevention strategies and novel therapeutics have certainly had a major role in this reduction; nevertheless, the future holds many more opportunities for improving cancer therapy.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:conflict-of-interest id="coi0005" view="all">
               <ce:section-title id="sect0055">Declaration of Competing Interest</ce:section-title>
               <ce:para id="par0185" view="all">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</ce:para>
            </ce:conflict-of-interest>
         </body>
         <tail view="all">
            <ce:bibliography id="bibl0005" view="all">
               <ce:section-title id="sect0060">References</ce:section-title>
               <ce:bibliography-sec id="bibs0005" view="all">
                  <ce:bib-reference id="bib0005">
                     <ce:label>1</ce:label>
                     <sb:reference id="sbref0005">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Watanabe</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Adult cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1-infected T cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>129</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1071</sb:first-page>
                              <sb:last-page>1082</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0020">Watanabe, T. (2017) Adult cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1-infected T cells. Blood 129, 1071–1082</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0010">
                     <ce:label>2</ce:label>
                     <sb:reference id="sbref0010">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Czabotar</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>49</sb:first-page>
                              <sb:last-page>63</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0025">Czabotar, P. et al. (2014) Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat. Rev. Cell Biol. 15, 49-63</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0015">
                     <ce:label>3</ce:label>
                     <sb:reference id="sbref0015">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.S.</ce:given-name>
                                 <ce:surname>Wong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Apoptosis in cancer: from pathogenesis to treatment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Exp. Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>30</sb:first-page>
                              <sb:last-page>87</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0030">Wong, R.S. (2011) Apoptosis in cancer: from pathogenesis to treatment. J. Exp. Clin. Cancer Res. 26, 30–87</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0020">
                     <ce:label>4</ce:label>
                     <sb:reference id="sbref0020">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Shimoyama</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Br. J. Haematol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>79</sb:volume-nr>
                              </sb:series>
                              <sb:date>1991</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>428</sb:first-page>
                              <sb:last-page>437</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0035">Shimoyama, M. (1991) Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group. Br. J. Haematol. 79, 428-437</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0025">
                     <ce:label>5</ce:label>
                     <sb:reference id="sbref0025">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Baldwin</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The NF-kappa B and I kappa B proteins: new discoveries and insights</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Annu. Rev. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>1996</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>649</sb:first-page>
                              <sb:last-page>683</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0040">Baldwin, Jr. (1996) The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 14, 649–683</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0030">
                     <ce:label>6</ce:label>
                     <sb:reference id="sbref0030">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Portis</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The contribution of NF-κB activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 Tax-induced tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>98</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1200</sb:first-page>
                              <sb:last-page>1208</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0045">Portis, T. et al. (2001) The contribution of NF-κB activity to spontaneous proliferation and resistance to apoptosis in human T-cell leukemia virus type 1 Tax-induced tumors. Blood 98, 1200–1208</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0035">
                     <ce:label>7</ce:label>
                     <sb:reference id="sbref0035">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Chie</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Peridinin, a carotenoid, inhibits proliferation and survival of HTLV-1-infected T-cell lines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>51</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>633</sb:first-page>
                              <sb:last-page>643</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0050">Chie, I. et al. (2016) Peridinin, a carotenoid, inhibits proliferation and survival of HTLV-1-infected T-cell lines. Int. J. Oncol. 51, 633–643</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0040">
                     <ce:label>8</ce:label>
                     <sb:reference id="sbref0040">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Chie</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Butein inhibits NF-κB, AP-1 and Akt activation in adult T-cell leukemia/lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>51</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>633</sb:first-page>
                              <sb:last-page>643</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0055">Chie, I. et al. (2017) Butein inhibits NF-κB, AP-1 and Akt activation in adult T-cell leukemia/lymphoma. Int. J. Oncol. 51, 633–643</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0045">
                     <ce:label>9</ce:label>
                     <sb:reference id="sbref0045">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ishikawa</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Anti-adult T-cell leukemia effects of brown algae fucoxanthin and its deacetylated product, fucoxanthinol</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>123</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2702</sb:first-page>
                              <sb:last-page>2712</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0060">Ishikawa, C. et al. (2008) Anti-adult T-cell leukemia effects of brown algae fucoxanthin and its deacetylated product, fucoxanthinol. Int. J. Cancer. 123, 2702–2712</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0050">
                     <ce:label>10</ce:label>
                     <sb:reference id="sbref0050">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Taeko</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>NIK-333 inhibits growth of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells in association with blockade of nuclear factor-KB signal pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>704</sb:first-page>
                              <sb:last-page>712</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0065">Taeko, O. (2006) NIK-333 inhibits growth of human T-cell leukemia virus type I-infected T-cell lines and adult T-cell leukemia cells in association with blockade of nuclear factor-KB signal pathway. Mol. Cancer Ther. 5, 704–712</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0055">
                     <ce:label>11</ce:label>
                     <sb:reference id="sbref0055">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Naoki</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Bay 11-7082 inhibits transcription factor NF-κB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>100</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1828</sb:first-page>
                              <sb:last-page>1834</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0070">Naoki, M. et al. (2002) Bay 11-7082 inhibits transcription factor NF-κB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood 100, 1828–1834</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0060">
                     <ce:label>12</ce:label>
                     <sb:reference id="sbref0060">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Shvarzbeyn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Huleihel</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Effect of propolis and caffeic acid phenethyl ester (CAPE) on NFκB activation by HTLV-1 Tax</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Antivir. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>90</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>108</sb:first-page>
                              <sb:last-page>115</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0075">Shvarzbeyn, J. and Huleihel, M. (2011) Effect of propolis and caffeic acid phenethyl ester (CAPE) on NFκB activation by HTLV-1 Tax. Antivir. Res. 90, 108–115.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0065">
                     <ce:label>13</ce:label>
                     <sb:reference id="sbref0065">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Machijima</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Anti-adult T-cell leukemia/lymphoma effects of indole-3-carbinol</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Retrovirology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0080">Machijima, Y. (2009) Anti-adult T-cell leukemia/lymphoma effects of indole-3-carbinol. Retrovirology 6, 7</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0070">
                     <ce:label>14</ce:label>
                     <sb:reference id="sbref0070">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Nakazato</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Anti-adult T-cell leukemia effects of a novel synthetic retinoid, Am80 (tamibarotene) through inhibition of NF-κB</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>99</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2286</sb:first-page>
                              <sb:last-page>2294</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0085">Nakazato, T. (2008) Anti-adult T-cell leukemia effects of a novel synthetic retinoid, Am80 (tamibarotene) through inhibition of NF-κB. Cancer Sci. 99, 2286–2294</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0075">
                     <ce:label>15</ce:label>
                     <sb:reference id="sbref0075">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yamaguchi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dichotomy of all-trans retinoic acid inducing signals for adult T-cell leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1010</sb:first-page>
                              <sb:last-page>1017</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0090">Yamaguchi, T. (2005) Dichotomy of all-trans retinoic acid inducing signals for adult T-cell leukemia. Leukemia 19, 1010–1017</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0080">
                     <ce:label>16</ce:label>
                     <sb:reference id="sbref0080">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Mariko</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-κB, as a strategy for chemoprevention and therapy of adult T-cell leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>106</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2462</sb:first-page>
                              <sb:last-page>2471</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0095">Mariko, W. et al. (2004) Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-κB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood 106, 2462–2471</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0085">
                     <ce:label>17</ce:label>
                     <sb:reference id="sbref0085">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Nishioka</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fludarabine induces apoptosis of human T-cell leukemia virus type 1-infected T cells via inhibition of the nuclear factor-<ce:italic>κ</ce:italic>B signal pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1044</sb:first-page>
                              <sb:last-page>1049</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0100">Nishioka, C. et al. (2007) Fludarabine induces apoptosis of human T-cell leukemia virus type 1-infected T cells via inhibition of the nuclear factor-κB signal pathway. Leukemia 21, 1044–1049</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0090">
                     <ce:label>18</ce:label>
                     <sb:reference id="sbref0090">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Nori</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein phosphatase 2A as a potential target for treatment of adult T cell leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Cancer Drug Targets</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>829</sb:first-page>
                              <sb:last-page>842</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0105">Nori, N. et al. (2013) Protein phosphatase 2A as a potential target for treatment of adult T cell leukemia. Curr. Cancer Drug Targets 13, 829–842</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0095">
                     <ce:label>19</ce:label>
                     <sb:reference id="sbref0095">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting autophagic regulation of NFkappaB in HTLV-I transformed cells by geldanamycin: implications for therapeutic interventions</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Autophagy</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>600</sb:first-page>
                              <sb:last-page>603</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0110">Yan, P. et al. (2007) Targeting autophagic regulation of NFkappaB in HTLV-I transformed cells by geldanamycin: implications for therapeutic interventions. Autophagy 3, 600–603</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0100">
                     <ce:label>20</ce:label>
                     <sb:reference id="sbref0100">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Chie</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Efficiency of AUY922 in mice with adult T-cell leukemia/lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncol. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>387</sb:first-page>
                              <sb:last-page>392</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0115">Chie, I. et al. (2016) Efficiency of AUY922 in mice with adult T-cell leukemia/lymphoma. Oncol. Lett. 12, 387–392</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0105">
                     <ce:label>21</ce:label>
                     <sb:reference id="sbref0105">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.Z.</ce:given-name>
                                 <ce:surname>Dewan</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>107</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>716</sb:first-page>
                              <sb:last-page>724</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0120">Dewan, M.Z. et al. (2006) Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir. Blood 107, 716–724</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0110">
                     <ce:label>22</ce:label>
                     <sb:reference id="sbref0110">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.A.</ce:given-name>
                                 <ce:surname>West</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activation of the PI3K/Akt pathway and chemotherapeutic resistance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Resist. Update</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>234</sb:first-page>
                              <sb:last-page>248</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0125">West, K.A. et al. (2002) Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Update 5, 234–248</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0115">
                     <ce:label>23</ce:label>
                     <sb:reference id="sbref0115">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Watanabe</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>mTOR signaling, function, novel inhibitors, and therapeutic targets</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Nuclear Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>52</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>497</sb:first-page>
                              <sb:last-page>500</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0130">Watanabe, R. et al. (2011) mTOR signaling, function, novel inhibitors, and therapeutic targets. J. Nuclear Med. 52, 497–500</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0120">
                     <ce:label>24</ce:label>
                     <sb:reference id="sbref0120">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Gutierrez</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>114</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>647</sb:first-page>
                              <sb:last-page>650</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0135">Gutierrez, A. et al. (2009) High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 114, 647–650</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0125">
                     <ce:label>25</ce:label>
                     <sb:reference id="sbref0125">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Masaaki</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Downregulation of CDKN1A in adult T-cell leukemia/lymphoma despite overexpression of CDKN1A in human T-lymphotropic virus 1-infected cell lines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Virol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>84</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6966</sb:first-page>
                              <sb:last-page>6977</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0140">Masaaki, W. (2010) Downregulation of CDKN1A in adult T-cell leukemia/lymphoma despite overexpression of CDKN1A in human T-lymphotropic virus 1-infected cell lines. J. Virol. 84, 6966–6977</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0130">
                     <ce:label>26</ce:label>
                     <sb:reference id="sbref0130">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Hiroo</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phosphatidylinositol 3-kinase-δ (PI3K-δ) is a potential therapeutic target in adult T-cell leukemia-lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biomarker Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>24</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0145">Hiroo, K. et al. (2018) Phosphatidylinositol 3-kinase-δ (PI3K-δ) is a potential therapeutic target in adult T-cell leukemia-lymphoma. Biomarker Res. 6, 24</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0135">
                     <ce:label>27</ce:label>
                     <sb:reference id="sbref0135">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ikezoe</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leuk. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>31</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>673</sb:first-page>
                              <sb:last-page>682</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0150">Ikezoe, T. et al. (2006) Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leuk. Res. 31, 673–682</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0140">
                     <ce:label>28</ce:label>
                     <sb:reference id="sbref0140">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ishikawa</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Effects of NVP-BEZ235, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, on HTLV-1-infected T-cell lines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncol. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5311</sb:first-page>
                              <sb:last-page>5317</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0155">Ishikawa, C. et al. (2018) Effects of NVP-BEZ235, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, on HTLV-1-infected T-cell lines. Oncol. Lett. 15, 5311–5317</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0145">
                     <ce:label>29</ce:label>
                     <sb:reference id="sbref0145">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Darwiche</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of mammalian target of rapamycin signaling by everolimus induces senescence in adult T-cell leukemia/lymphoma and apoptosis in peripheral T-cell lymphomas</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>129</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>993</sb:first-page>
                              <sb:last-page>1004</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0160">Darwiche, N. et al. (2011) Inhibition of mammalian target of rapamycin signaling by everolimus induces senescence in adult T-cell leukemia/lymphoma and apoptosis in peripheral T-cell lymphomas. Int. J. Cancer 129, 993–1004</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0150">
                     <ce:label>30</ce:label>
                     <sb:reference id="sbref0150">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Watanabe</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Torin2 potentiates anticancer effects on adult T-cell leukemia/lymphoma by inhibiting mammalian target of rapamycin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anticancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>36</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>95</sb:first-page>
                              <sb:last-page>102</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0165">Watanabe, T. et al. (2016) Torin2 potentiates anticancer effects on adult T-cell leukemia/lymphoma by inhibiting mammalian target of rapamycin. Anticancer Res. 36, 95–102</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0155">
                     <ce:label>31</ce:label>
                     <sb:reference id="sbref0155">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Sinha-Datta</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Celecoxib disrupts the canonical apoptotic network in HTLV-I cells through activation of Bax and inhibition of PKB/Akt</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Apoptosis</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>33</sb:first-page>
                              <sb:last-page>40</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0170">Sinha-Datta, U. et al. (2008) Celecoxib disrupts the canonical apoptotic network in HTLV-I cells through activation of Bax and inhibition of PKB/Akt. Apoptosis 13, 33–40</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0160">
                     <ce:label>32</ce:label>
                     <sb:reference id="sbref0160">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Oki</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Br. J. Haematol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>171</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>463</sb:first-page>
                              <sb:last-page>470</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0175">Oki, Y. et al. (2015) Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br. J. Haematol. 171, 463–470</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0165">
                     <ce:label>33</ce:label>
                     <sb:reference id="sbref0165">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Iyer</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pooled safety analysis and efficacy of Tenalisib (RP6530), a PI3Kδ/γ inhibitor, in patients with relapsed/refractory lymphoid malignancies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>132</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>2925–2925</sb:comment>
                     </sb:reference>
                     <ce:source-text id="sot0180">Iyer, S.P. et al. (2018) Pooled safety analysis and efficacy of Tenalisib (RP6530), a PI3Kδ/γ inhibitor, in patients with relapsed/refractory lymphoid malignancies. Blood 132, 2925–2925</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0170">
                     <ce:label>34</ce:label>
                     <sb:reference id="sbref0170">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Patnaik</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin’s lymphomas</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1928</sb:first-page>
                              <sb:last-page>1940</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0185">Patnaik, A. et al. (2016) First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin’s lymphomas. Ann. Oncol. 27, 1928–1940</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0175">
                     <ce:label>35</ce:label>
                     <sb:reference id="sbref0175">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Tomita</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of constitutively active Jak-Stat pathway suppresses cell growth of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Retrovirology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>22</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0190">Tomita, M. et al. (2006) Inhibition of constitutively active Jak-Stat pathway suppresses cell growth of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. Retrovirology 3, 22</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0180">
                     <ce:label>36</ce:label>
                     <sb:reference id="sbref0180">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AZ960, a novel Jak2 inhibitor, induces growth arrest and apoptosis in adult T-Cell leukemia cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3386</sb:first-page>
                              <sb:last-page>3395</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0195">Yang, J. et al. (2010) AZ960, a novel Jak2 inhibitor, induces growth arrest and apoptosis in adult T-Cell leukemia cells. Mol. Cancer Ther. 9, 3386-3395</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0185">
                     <ce:label>37</ce:label>
                     <sb:reference id="sbref0185">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ito</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Deguelin suppresses cell proliferation via the inhibition of survivin expression and STAT3 phosphorylation in HTLV-1-transformed T cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leuk. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>34</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>352</sb:first-page>
                              <sb:last-page>357</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0200">Ito, S. et al. (2009) Deguelin suppresses cell proliferation via the inhibition of survivin expression and STAT3 phosphorylation in HTLV-1-transformed T cells. Leuk. Res. 34, 352–357</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0190">
                     <ce:label>38</ce:label>
                     <sb:reference id="sbref0190">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yuzo</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Resveratrol suppresses cell proliferation via inhibition of STAT3 phosphorylation and Mcl-1 and cIAP-2 expression in HTLV-1-infected T cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leuk. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>37</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1674</sb:first-page>
                              <sb:last-page>1679</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0205">Yuzo, S. et al. (2013) Resveratrol suppresses cell proliferation via inhibition of STAT3 phosphorylation and Mcl-1 and cIAP-2 expression in HTLV-1-infected T cells. Leuk. Res. 37, 1674–1679</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0195">
                     <ce:label>39</ce:label>
                     <sb:reference id="sbref0195">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bellon</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>127</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2439</sb:first-page>
                              <sb:last-page>2450</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0210">Bellon, M. et al. (2016) Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia. Blood 127, 2439–2450</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0200">
                     <ce:label>40</ce:label>
                     <sb:reference id="sbref0200">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective γ-chain cytokines, decreases leukemic T-cell viability</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1243</sb:first-page>
                              <sb:last-page>1255</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0215">Wang, T. et al. (2018) IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective γ-chain cytokines, decreases leukemic T-cell viability. Leukemia 33, 1243–1255</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0205">
                     <ce:label>41</ce:label>
                     <sb:reference id="sbref0205">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Jasmine</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aggressive T‐cell lymphomas: 2019 updates on diagnosis, risk stratification, and management</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Am. J. Hematol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>94</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>929</sb:first-page>
                              <sb:last-page>946</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0220">Jasmine, Z. (2019) Aggressive T‐cell lymphomas: 2019 updates on diagnosis, risk stratification, and management. Am. J. Hematol. 94, 929–946</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0210">
                     <ce:label>42</ce:label>
                     <sb:reference id="sbref0210">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Krueger</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>HTLV-1 Tax protects against CD95-mediated apoptosis by induction of the cellular FLICE-inhibitory protein (c-FLIP)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>107</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3933</sb:first-page>
                              <sb:last-page>3939</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0225">Krueger, A. et al. (2006) HTLV-1 Tax protects against CD95-mediated apoptosis by induction of the cellular FLICE-inhibitory protein (c-FLIP). Blood 107, 3933–3939</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0215">
                     <ce:label>43</ce:label>
                     <sb:reference id="sbref0215">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Saitoh</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A20 targets caspase-8 and FADD to protect HTLV-I infected cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>716</sb:first-page>
                              <sb:last-page>727</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0230">Saitoh, Y. et al. (2016) A20 targets caspase-8 and FADD to protect HTLV-I infected cells. Leukemia. 30, 716–727</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0220">
                     <ce:label>44</ce:label>
                     <sb:reference id="sbref0220">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hiaki</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Multi-step aberrant CpG island hyper-methylation is associated with the progression of adult T-cell leukemia/lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Am. J. Pathol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>176</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>402</sb:first-page>
                              <sb:last-page>415</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0235">Hiaki, S. et al. (2010) Multi-step aberrant CpG island hyper-methylation is associated with the progression of adult T-cell leukemia/lymphoma. Am. J. Pathol. 176, 402–415</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0225">
                     <ce:label>45</ce:label>
                     <sb:reference id="sbref0225">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Macaire</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tax protein-induced expression of antiapoptotic Bfl-1 protein contributes to survival of human T-cell leukemia virus type 1 (HTLV-1)-infected T-cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>287</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>21357</sb:first-page>
                              <sb:last-page>21370</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0240">Macaire, H. et al. (2012) Tax protein-induced expression of antiapoptotic Bfl-1 protein contributes to survival of human T-cell leukemia virus type 1 (HTLV-1)-infected T-cells. J. Biol. Chem. 287, 21357-21370</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0230">
                     <ce:label>46</ce:label>
                     <sb:reference id="sbref0230">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Tanaka-Nakanishi</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>HTLV-1 bZIP factor suppresses apoptosis by attenuating the function of FoxO3a and altering its localization</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>74</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>188</sb:first-page>
                              <sb:last-page>200</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0245">Tanaka-Nakanishi, A. et al. (2014) HTLV-1 bZIP factor suppresses apoptosis by attenuating the function of FoxO3a and altering its localization. Cancer Res. 74, 188-200</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0235">
                     <ce:label>47</ce:label>
                     <sb:reference id="sbref0235">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Tomohiro</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The small molecule STF-62247 induces apoptotic and autophagic cell death in leukemic cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>27645</sb:first-page>
                              <sb:last-page>27655</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0250">Tomohiro, K. et al. (2018) The small molecule STF-62247 induces apoptotic and autophagic cell death in leukemic cells. Oncotarget 9, 27645-27655</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0240">
                     <ce:label>48</ce:label>
                     <sb:reference id="sbref0240">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Tomohiro</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel small molecule SIRT2 inhibitors induce cell death in leukemic cell lines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>BMC Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>791</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0255">Tomohiro, K. et al. (2018) Novel small molecule SIRT2 inhibitors induce cell death in leukemic cell lines. BMC Cancer18, 791</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0245">
                     <ce:label>49</ce:label>
                     <sb:reference id="sbref0245">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Tsumuraya</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>81</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>713</sb:first-page>
                              <sb:last-page>722</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0260">Tsumuraya, T. et al. (2016) Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia. Biochem. Pharmacol. 81, 713-722</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0250">
                     <ce:label>50</ce:label>
                     <sb:reference id="sbref0250">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kozaki</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T-cell leukemia cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>FEBS Open Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>442</sb:first-page>
                              <sb:last-page>460</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0265">Kozaki, T. et al. (2016) Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T-cell leukemia cells. FEBS Open Biol. 6, 442-460</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0255">
                     <ce:label>51</ce:label>
                     <sb:reference id="sbref0255">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Moles</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>WRN-targeted therapy using inhibitors NSC 19630 and NSC 617145 induce apoptosis in HTLV-1-transformed adult T-cell leukemia cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Hematol. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>121</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0270">Moles, R. et al. (2016) WRN-targeted therapy using inhibitors NSC 19630 and NSC 617145 induce apoptosis in HTLV-1-transformed adult T-cell leukemia cells. J. Hematol. Oncol. 9, 121</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0260">
                     <ce:label>52</ce:label>
                     <sb:reference id="sbref0260">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Naoko</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Anticancer effects of phenoxazine derivatives revealed by inhibition of cell growth and viability, disregulation of cell cycle, and apoptosis induction in HTLV-1-positive leukemia cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Pharmacol. Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>110</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>87</sb:first-page>
                              <sb:last-page>97</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0275">Naoko, M. et al. (2009) Anticancer effects of phenoxazine derivatives revealed by inhibition of cell growth and viability, disregulation of cell cycle, and apoptosis induction in HTLV-1-positive leukemia cells. J. Pharmacol. Sci. 110, 87–97</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0265">
                     <ce:label>53</ce:label>
                     <sb:reference id="sbref0265">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Tomohiro</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>High expression of the longevity gene product SIRT1 and apoptosis induction by sirtinol in adult T‐cell leukemia cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>131</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2044</sb:first-page>
                              <sb:last-page>2055</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0280">Tomohiro, K. et al. (2012) High expression of the longevity gene product SIRT1 and apoptosis induction by sirtinol in adult T‐cell leukemia cells. Int. J. Cancer. 131, 2044–2055</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0270">
                     <ce:label>54</ce:label>
                     <sb:reference id="sbref0270">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Woo</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Apoptogenic activity of 2α,3α-dihydroxyurs-12-ene-28-oic acid from <ce:italic>Prunella vulgaris</ce:italic> var. <ce:italic>lilacina</ce:italic> is mediated via mitochondria-dependent activation of caspase cascade regulated by Bcl-2 in human acute leukemia Jurkat T cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Ethnopharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>135</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>626</sb:first-page>
                              <sb:last-page>635</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0285">Woo, H. et al. (2011) Apoptogenic activity of 2α,3α-dihydroxyurs-12-ene-28-oic acid from Prunella vulgaris var. lilacina is mediated via mitochondria-dependent activation of caspase cascade regulated by Bcl-2 in human acute leukemia Jurkat T cells. J. Ethnopharmacol. 135, 626–635</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0275">
                     <ce:label>55</ce:label>
                     <sb:reference id="sbref0275">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Rajneela</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Apoptotic and autophagic effects of <ce:italic>Sesbania grandiflora</ce:italic> flowers in human leukemic cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS One</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:article-number>e71672</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0290">Rajneela, R. et al. (2013) Apoptotic and autophagic effects of Sesbania grandiflora flowers in human leukemic cells. PLoS ONE 8, e71672</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0280">
                     <ce:label>56</ce:label>
                     <sb:reference id="sbref0280">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mallick</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Corchorusin-D, a saikosaponin-like compound isolated from <ce:italic>Corchorus acutangulus</ce:italic> Lam., targets mitochondrial apoptotic pathways in leukemic cell lines (HL-60 and U937)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Chemother. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>66</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>709</sb:first-page>
                              <sb:last-page>719</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0295">Mallick, S. et al. (2010) Corchorusin-D, a saikosaponin-like compound isolated from Corchorus acutangulus Lam., targets mitochondrial apoptotic pathways in leukemic cell lines (HL-60 and U937). Cancer Chemother. Pharmacol. 66, 709–719</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0285">
                     <ce:label>57</ce:label>
                     <sb:reference id="sbref0285">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Georges</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>111</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3770</sb:first-page>
                              <sb:last-page>3777</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0300">Georges, M. et al. (2008) EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma. Blood. 111, 3770–3777</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0290">
                     <ce:label>58</ce:label>
                     <sb:reference id="sbref0290">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>U-Taniguchi</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cell cycle inhibition of HTLV-I transformed T cell lines by retinoic acid: the possible therapeutic use of thioredoxin reductase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncol. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>183</sb:first-page>
                              <sb:last-page>189</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0305">U-Taniguchi, Y. et al. (1995) Cell cycle inhibition of HTLV-I transformed T cell lines by retinoic acid: the possible therapeutic use of thioredoxin reductase inhibitors. Oncol. Res. 7, 183–189</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0295">
                     <ce:label>59</ce:label>
                     <sb:reference id="sbref0295">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Guimaraes-Correa</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>C7a, a biphosphinic cyclopalladated compound, efficiently controls the development of a patient-derived xenograft model of adult T cell leukemia/lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Viruses</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1041</sb:first-page>
                              <sb:last-page>1058</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0310">Guimaraes-Correa, A. (2011) C7a, a biphosphinic cyclopalladated compound, efficiently controls the development of a patient-derived xenograft model of adult T cell leukemia/lymphoma. Viruses 3, 1041–1058</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0300">
                     <ce:label>60</ce:label>
                     <sb:reference id="sbref0300">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ishitsuka</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> effects of the novel Bcl-2 family inhibitor ABT-737</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>317</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>218</sb:first-page>
                              <sb:last-page>225</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0315">Ishitsuka, K. et al. (2012) Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737. Cancer Lett. 317, 218–225</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0305">
                     <ce:label>61</ce:label>
                     <sb:reference id="sbref0305">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Hypericin-photodynamic therapy inhibits the growth of adult T-cell leukemia cells through induction of apoptosis and suppression of viral transcription</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Retrovirology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0320">Xu, L. et al. (2019) Hypericin-photodynamic therapy inhibits the growth of adult T-cell leukemia cells through induction of apoptosis and suppression of viral transcription. Retrovirology 16, 5</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0310">
                     <ce:label>62</ce:label>
                     <sb:reference id="sbref0310">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>El Hajj</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Preclinical efficacy of the synthetic retinoid ST1926 for treating adult T-cell leukemia/lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>124</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2072</sb:first-page>
                              <sb:last-page>2080</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0325">El Hajj, H. et al. (2014) Preclinical efficacy of the synthetic retinoid ST1926 for treating adult T-cell leukemia/lymphoma. Blood 124, 2072–2080</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0315">
                     <ce:label>63</ce:label>
                     <sb:reference id="sbref0315">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Ju</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Combination of 9-aminoacridine with Campath-1H provides effective therapy for a murine model of adult T-cell leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Retrovirology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>43</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0330">Ju, W. et al. (2014) Combination of 9-aminoacridine with Campath-1H provides effective therapy for a murine model of adult T-cell leukemia. Retrovirology 11, 43</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0320">
                     <ce:label>64</ce:label>
                     <sb:reference id="sbref0320">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.T.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small PARP inhibitor PJ-34 induces cell cycle arrest and apoptosis of adult T-cell leukemia cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Hematol. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>117</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0335">Bai, X.T. et al. (2015) Small PARP inhibitor PJ-34 induces cell cycle arrest and apoptosis of adult T-cell leukemia cells. J. Hematol. Oncol. 8, 117</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0325">
                     <ce:label>65</ce:label>
                     <sb:reference id="sbref0325">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Takayuki</ce:given-name>
                                 <ce:surname>Hamasaki</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Selective inhibition of HTLV-1-infected cell proliferation by a novel tetramethylnaphthalene derivative</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anticancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>31</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2241</sb:first-page>
                              <sb:last-page>2248</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0340">Takayuki, Hamasaki. et al. (2011) Selective inhibition of HTLV-1-infected cell proliferation by a novel tetramethylnaphthalene derivative. Anticancer Res. 31, 2241–2248</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0330">
                     <ce:label>66</ce:label>
                     <sb:reference id="sbref0330">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ishikawa</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Honokiol induces cell cycle arrest and apoptosis via inhibition of survival signals in adult T-cell leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochim. Biophys. Acta</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1820</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>879</sb:first-page>
                              <sb:last-page>887</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0345">Ishikawa, C. et al. (2012) Honokiol induces cell cycle arrest and apoptosis via inhibition of survival signals in adult T-cell leukemia. Biochim. Biophys. Acta 1820, 879–887</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0335">
                     <ce:label>67</ce:label>
                     <sb:reference id="sbref0335">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Hsatomi</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase IIα and DNA-dependent protein kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>117</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3575</sb:first-page>
                              <sb:last-page>3584</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0350">Hsatomi, T. et al. (2011) NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase IIα and DNA-dependent protein kinase. Blood 117, 3575–3584</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0340">
                     <ce:label>68</ce:label>
                     <sb:reference id="sbref0340">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Narita</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>130</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1114</sb:first-page>
                              <sb:last-page>1124</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0355">Narita, T. et al. (2017) Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma. Blood 130, 1114–1124</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0345">
                     <ce:label>69</ce:label>
                     <sb:reference id="sbref0345">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bleumink</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Rocaglamide breaks TRAIL resistance in HTLV-1-associated adult T-cell leukemia/lymphoma by translational suppression of c-FLIP expression</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Death Differ.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>362</sb:first-page>
                              <sb:last-page>370</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0360">Bleumink, M. et al. (2011) Rocaglamide breaks TRAIL resistance in HTLV-1-associated adult T-cell leukemia/lymphoma by translational suppression of c-FLIP expression. Cell Death Differ. 18, 362–370</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib0350">
                     <ce:label>70</ce:label>
                     <sb:reference id="sbref0350">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Houssein</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Thymoquinone synergizes with arsenic and interferon alpha to target human T-cell leukemia/lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Life Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>251</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>117639</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="sot0365">Houssein, M et al. (2020) Thymoquinone synergizes with arsenic and interferon alpha to target human T-cell leukemia/lymphoma. Life Sci. 251, 117639</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>